Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Michael Stocum
AddedMar 31, 2024
UpdatedMay 31, 2026
Michael Stocum

Michael Stocum

CEO, Bantam Pharmaceutical

CrunchbaseLinkedIn

Michael Stocum's Career

Bantam Pharmaceutical
Bantam Pharmaceutical

New York City, NY, US

CEO· C-Suite · Management
BioFluidica
BioFluidica

San Diego, CA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Michael Stocum's Career

Bantam Pharmaceutical
Bantam Pharmaceutical
Seed$25M72015New York City, NY, US
CEO· C-Suite · Management

Similar to Bantam Pharmaceutical

Bakx TherapeuticsBakx TherapeuticsKingston, NY, USCancer Treatmentest. 2020Bakx TherapeuticsKingston, NY, US · est. 2020

BAKX Therapeutics: Leading provider of innovative cancer treatments.

Series A · $25M40
NantBioNantBioCulver City, CA, USPharmaceuticalsNantBioCulver City, CA, US

NantBioscience: LA-based developer of targeted pharmaceuticals for cancer treatment.

Late Stage Private · $180.1M75
OncoTartisOncoTartisBuffalo, NY, USAnti-Cancer Drugsest. 2011OncoTartisBuffalo, NY, US · est. 2011

OncoTartis, Inc.: A private biotech firm innovating targeted anti-cancer drugs for specific malignancies.

Series A · $6M8
Camino PharmaCamino PharmaSan Diego, CA, USCancer Treatment, Drug Developmentest. 2014Camino PharmaSan Diego, CA, US · est. 2014

Camino Pharma: A tech startup pioneering first-in-class cancer and CNS disorder therapies.

Seed · $13.7M3
BioFluidica
BioFluidica
Series B$19.2M192006San Diego, CA, US
Board Member· Board

Leadership at BioFluidica

Rolf MullerRolf MullerCEO
Sam TetlowSam TetlowBoard Member
Steve SoperSteve SoperFounder

Similar to BioFluidica

BioCeryxBioCeryxMenlo Park, CA, USDiagnostic Platformsest. 2017BioCeryxMenlo Park, CA, US · est. 2017

BioCeryx: Developing accessible molecular diagnostic platforms through fluidics, engineering, and bioinformatics.

Series A · $5M30
Biological DynamicsBiological DynamicsSan Diego, CA, USDiagnostics, Treatmentest. 2010Biological DynamicsSan Diego, CA, US · est. 2010

Biological Dynamics Inc. develops technology for capturing large molecular particles, aiding in diagnosis and treatment.

Series D · $43.8M99
FluidigmFluidigmSouth San Francisco, CA, USBiotechnologyest. 1999FluidigmSouth San Francisco, CA, US · est. 1999

Standard BioTools Inc., based in South San Francisco, accelerates life sciences research with essential, standardized technologies.

Public615

Michael Stocum's Similar Executives & Operators

Willix HalimWillix HalimCEO · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · Kakao

People Similar to Michael Stocum

Venkat KrishnanVenkat KrishnanCEO · BionpharmaJohn FunkhouserJohn FunkhouserCEO · PharmaneticsRonald GoldRonald GoldBoard Member · NJ BioPaul B. DumondPaul B. DumondCEO · Bioscience Pharma PartnersJames LynchJames LynchCEO · NanoPharmaceuticalsJohn KallassyJohn KallassyCEO · Bactana